Dicerna Pharmaceuticals
Delivering RNAi-based breakthrough therapies to improve lives.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD4.5b (Public information from Nov 2021)
Share price
$38.22 DRNA
Watertown Massachusetts (HQ)
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 1.0m | 6.0m | 23.0m | 164m | 193m | 191m |
| % growth | - | - | 500 % | 283 % | 613 % | 18 % | (1 %) |
| EBITDA | - | (50.0m) | (60.0m) | (127m) | (111m) | (142m) | (213m) |
| % EBITDA margin | - | (5000 %) | (1000 %) | (552 %) | (68 %) | (74 %) | (112 %) |
| Profit | - | (60.0m) | (88.0m) | (120m) | (113m) | (127m) | (149m) |
| % profit margin | - | (6000 %) | (1467 %) | (522 %) | (69 %) | (66 %) | (78 %) |
| EV / revenue | - | 466.0x | 111.8x | 51.4x | 6.9x | - | - |
| EV / EBITDA | - | -9.3x | -11.2x | -9.3x | -10.2x | - | - |
| R&D budget | 39.6m | 28.6m | 35.2m | 78.1m | - | - | - |
| R&D % of revenue | - | 2860 % | 587 % | 340 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$8.4m | Series A | ||
$124m | Early VC | ||
| N/A | $29.1m | Series B | |
$4.0m | Series B | ||
$60.0m | Series C | ||
| N/A | N/A | IPO | |
* | N/A | N/A | Post IPO Equity |
$70.0m | Post IPO Equity | ||
* | N/A | $100m | Post IPO Equity |
$100m | Post IPO Equity | ||
* | $3.3b Valuation: $3.3b 20.1x EV/LTM Revenues -29.7x EV/LTM EBITDA | Acquisition | |
| Total Funding | CAD308m | ||
Recent News about Dicerna Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.